InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.205 0.005 (2.38%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$123 EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENT 27 Aug 2018 9:26AM $0.087 $0.205 risen by 135.63%
$123 Quarterly Review & Appendix 4C 31 Jul 2018 9:51AM $0.093 $0.205 risen by 120.43%
$123 Company Presentation 27 Jul 2018 9:29AM $0.098 $0.205 risen by 109.18%
$123 Change of Director Interest Notices x 2 24 Jul 2018 9:38AM $0.100 $0.205 risen by 105%
$123 Ethics Approval Received Appendix 3B and S.708A Notice 18 Jul 2018 9:22AM $0.095 $0.205 risen by 115.79%
$123 Further US patent allowed for DMX-200 2 Jul 2018 8:28AM n/a $0.205 n/a
$123 Investor Presentation 20 Jun 2018 9:12AM $0.105 $0.205 risen by 95.24%
$123 Change of Director's Interest Notice 30 May 2018 8:21AM $0.099 $0.205 risen by 107.07%
$123 Change of Director's Interest Notice 29 May 2018 12:37PM $0.098 $0.205 risen by 109.18%
$123 Dual Phase 2 trials launched for CKD 15 May 2018 8:46AM $0.110 $0.205 risen by 86.36%
$123 LEAD INVESTIGATOR ENGAGED FOR NEXT STAGE OF DMX-200 TRIALS 7 May 2018 10:05AM $0.120 $0.205 risen by 70.83%
$123 Completion of Unmarketable Parcel Sale Facility 2 May 2018 3:29PM $0.120 $0.205 risen by 70.83%
$123 Dimerix to Further Bolster Management Team 30 Apr 2018 9:33AM $0.110 $0.205 risen by 86.36%
$123 Quarterly Review & Appendix 4C 27 Apr 2018 9:07AM $0.110 $0.205 risen by 86.36%
$123 NDF Research updated analyst coverage 13 Apr 2018 9:20AM $0.115 $0.205 risen by 78.26%
$123 Westar Capital Retained as Corporate Advisors 12 Apr 2018 1:46PM $0.110 $0.205 risen by 86.36%
$123 CMO Appointment and Clinical Trials Update 27 Mar 2018 9:18AM $0.125 $0.205 risen by 64%
$123 Channel 7 News Segment 13 Mar 2018 11:29AM $0.145 $0.205 risen by 41.38%
$123 Unmarketable Parcel Share Sale Facility 9 Mar 2018 9:24AM $0.135 $0.205 risen by 51.85%
$123 Ceasing to be a substantial holder 1 Mar 2018 12:04PM $0.145 $0.205 risen by 41.38%
$123 Change in substantial holding 28 Feb 2018 1:24PM $0.140 $0.205 risen by 46.43%
$123 LR 3.10.5A Disclosure 28 Feb 2018 10:05AM $0.145 $0.205 risen by 41.38%
$123 Appendix 3B and Cleansing Notice 28 Feb 2018 9:54AM $0.145 $0.205 risen by 41.38%
$123 Change in substantial holding 27 Feb 2018 12:35PM $0.150 $0.205 risen by 36.67%
$123 Half Year Report and Financial Statements 26 Feb 2018 7:27PM $0.150 $0.205 risen by 36.67%

576 - 600 of 746 results

Page 24 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.